Dynamic DNA Methylation Regulates Levodopa-Induced Dyskinesia

被引:30
|
作者
Figge, David A. [1 ]
Jaunarajs, Karen L. Eskow [1 ]
Standaert, David G. [1 ]
机构
[1] Univ Alabama Birmingham, Ctr Neurodegenerat & Expt Therapeut, Dept Neurol, Birmingham, AL 35294 USA
来源
JOURNAL OF NEUROSCIENCE | 2016年 / 36卷 / 24期
关键词
DNA methylation; dyskinesia; L-DOPA; DOPA-INDUCED DYSKINESIA; PARKINSONS-DISEASE; GENE-EXPRESSION; PROJECTION NEURONS; NUCLEUS-ACCUMBENS; MEMORY FORMATION; PLASTICITY; 5-HYDROXYMETHYLCYTOSINE; DEMETHYLATION; TRANSCRIPTION;
D O I
10.1523/JNEUROSCI.0683-16.2016
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Levodopa-induced dyskinesia (LID) is a persistent behavioral sensitization that develops after repeated levodopa (L-DOPA) exposure in Parkinson disease patients. LID is a consequence of sustained changes in the transcriptional behavior of striatal neurons following dopaminergic stimulation. In neurons, transcriptional regulation through dynamic DNA methylation has been shown pivotal to many long-term behavioral modifications; however, its role in LID has not yet been explored. Using a rodent model, we show LID development leads to the aberrant expression of DNA demethylating enzymes and locus-specific changes to DNA methylation at the promoter regions of genes aberrantly transcribed following L-DOPA treatment. Looking for dynamic DNA methylation in LID genome- wide, we used reduced representation bisulfite sequencingand found an extensive reorganization of the dorsal striatal methylome. LID development led to significant demethylation at many important regulatory areas of aberrantly transcribed genes. We used pharmacologic treatments that alter DNA methylation bidirectionally and found them able to modulate dyskinetic behaviors. Together, these findings demonstrate that L-DOPA induces widespread changes to striatal DNA methylation and that these modifications are required for the development and maintenance of LID.
引用
收藏
页码:6514 / 6524
页数:11
相关论文
共 50 条
  • [1] Reversal of Levodopa-Induced Dyskinesia
    Alias, Mathew
    Hassan, Mohamed
    ANNALS OF NEUROLOGY, 2012, 72 : S91 - S91
  • [2] Predicting levodopa-induced dyskinesia
    Kempster, Peter
    ARQUIVOS DE NEURO-PSIQUIATRIA, 2020, 78 (04) : 185 - 186
  • [3] Treatment of levodopa-induced dyskinesia
    Rao J.
    Current Treatment Options in Neurology, 2007, 9 (3) : 205 - 209
  • [4] Management of levodopa-induced dyskinesia
    Rascol, O
    Ferreira, JJ
    Payoux, R
    Brefel-Courbon, C
    Montastruc, JL
    REVUE NEUROLOGIQUE, 2002, 158 : S117 - S124
  • [5] LEVODOPA-INDUCED DYSKINESIA AND THALAMOTOMY
    NARABAYASHI, H
    YOKOCHI, F
    NAKAJIMA, Y
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1984, 47 (08): : 831 - 839
  • [6] Riluzole Administration to Rats with Levodopa-Induced Dyskinesia Leads to Loss of DNA Methylation in Neuronal Genes
    Pagliaroli, Luca
    Fothi, Abel
    Nespoli, Ester
    Liko, Istvan
    Veto, Borbala
    Devay, Piroska
    Szeri, Flora
    Hengerer, Bastian
    Barta, Csaba
    Aranyi, Tamas
    CELLS, 2021, 10 (06)
  • [7] Automated Levodopa-Induced Dyskinesia Assessment
    Tsipouras, Markos G.
    Tzallas, Alexandros T.
    Rigas, Georgios
    Bougia, Panagiota
    Fotiadis, Dimitrios I.
    Konitsiotis, Spyridon
    2010 ANNUAL INTERNATIONAL CONFERENCE OF THE IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY (EMBC), 2010, : 2411 - 2414
  • [9] Nondopaminergic mechanisms in levodopa-induced dyskinesia
    Brotchie, JA
    MOVEMENT DISORDERS, 2005, 20 (08) : 919 - 931
  • [10] CYPROHEPTADINE IN LEVODOPA-INDUCED DYSKINESIA IN PARKINSONISM
    PAPAVASILIOU, PS
    COTZIAS, GC
    MCDOWELL, FH
    ROSAL, VLF
    SHEEHAN, PJ
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1978, 23 (02) : 195 - 198